Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Study to Determine the Short-Term Safety of Continuous Dosing of Abiraterone Acetate and Prednisone in Modified Fasting and Fed States to Patients With Metastatic Castration-Resistant Prostate Cancer

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Janssen-Ortho Inc., Canada
ClinicalTrials.gov Identifier:
NCT01424930
First received: August 26, 2011
Last updated: July 14, 2014
Last verified: July 2014
Results First Received: March 28, 2014  
Study Type: Interventional
Study Design: Allocation: Non-Randomized;   Endpoint Classification: Safety Study;   Intervention Model: Parallel Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Conditions: Prostate Neoplasms
Prostate Cancer
Interventions: Drug: Abiraterone
Drug: Prednisone

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
The study was conducted from 29 September 2011 to 29 May 2013. Participants were recruited at 2 study centers in Canada.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Abiraterone+Prednisone (Low-fat Meal) Participants received abiraterone acetate at a starting dose of 1,000 milligram (mg) once daily for 7 days post 30-minutes of a standardized low-fat meal from Cycle 1 Day 8 to Cycle 1 Day 14. Prednisone was administered as 5 mg oral tablet twice daily during Cycle 1 Day 8 to Cycle 1 Day 14.
Abiraterone+Prednisone (High-fat Meal) Participants received abiraterone acetate at a starting dose of 1,000 mg once daily for 7 days post 30-minutes of a standardized high-fat meal from Cycle 1 Day 8 to Cycle 1 Day 14. Prednisone was administered as 5 mg oral tablet twice daily during Cycle 1 Day 8 to Cycle 1 Day 14

Participant Flow:   Overall Study
    Abiraterone+Prednisone (Low-fat Meal)     Abiraterone+Prednisone (High-fat Meal)  
STARTED     7     18  
Completed Food Safety Evaluation     6     18  
COMPLETED     3     4  
NOT COMPLETED     4     14  
Adverse Event                 0                 1  
Death                 1                 0  
Progressive Disease                 3                 6  
Screen Failure                 0                 1  
Reason not specified                 0                 6  



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Abiraterone+Prednisone (Low-fat Meal) Participants received abiraterone acetate at a starting dose of 1,000 milligram (mg) once daily for 7 days post 30-minutes of a standardized low-fat meal from Cycle 1 Day 8 to Cycle 1 Day 14. Prednisone was administered as 5 mg oral tablet twice daily during Cycle 1 Day 8 to Cycle 1 Day 14.
Abiraterone+Prednisone (High-fat Meal) Participants received abiraterone acetate at a starting dose of 1,000 mg once daily for 7 days post 30-minutes of a standardized high-fat meal from Cycle 1 Day 8 to Cycle 1 Day 14. Prednisone was administered as 5 mg oral tablet twice daily during Cycle 1 Day 8 to Cycle 1 Day 14
Total Total of all reporting groups

Baseline Measures
    Abiraterone+Prednisone (Low-fat Meal)     Abiraterone+Prednisone (High-fat Meal)     Total  
Number of Participants  
[units: participants]
  7     18     25  
Age  
[units: years]
Mean ± Standard Deviation
  75.1  ± 11.01     69.1  ± 7.26     70.8  ± 8.67  
Gender  
[units: participants]
     
Female     0     0     0  
Male     7     18     25  



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Number of Participants With Grade 3 or Higher Adverse Events (AEs) of Special Interest or Grade 3 or Higher Serious AEs Due to Study Medication   [ Time Frame: Postdose on Cycle 1 Day 8 to predose on Cycle 2 Day 1 ]

2.  Secondary:   Maximum Observed Plasma Concentration (Cmax) of Abiraterone   [ Time Frame: Day 7 and Day 14 ]

3.  Secondary:   Time to Reach Maximum Observed Plasma Concentration (Tmax) of Abiraterone   [ Time Frame: Day 7 and Day 14 ]

4.  Secondary:   Area Under the Plasma Concentration-time Curve From the Time of Administration to 24 Hours After Dosing (AUC24h)   [ Time Frame: Day 7 and Day 14 ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed.


Results Point of Contact:  
Name/Title: Senior Director
Organization: Janssen R&D US
e-mail: ClinicalTrialDisclosure@its.jnj.com


No publications provided


Responsible Party: Janssen-Ortho Inc., Canada
ClinicalTrials.gov Identifier: NCT01424930     History of Changes
Other Study ID Numbers: CR018715, 212082PCR2008
Study First Received: August 26, 2011
Results First Received: March 28, 2014
Last Updated: July 14, 2014
Health Authority: Canada: Health Canada